

# Linda B Adams

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/605515/publications.pdf>

Version: 2024-02-01

8  
papers

176  
citations

1478505

6  
h-index

1588992

8  
g-index

8  
all docs

8  
docs citations

8  
times ranked

222  
citing authors

| # | ARTICLE  | IF  | CITATIONS |
|---|--|-----|-----------|
| 1 | Molecular Assays for Determining <i>Mycobacterium leprae</i> Viability in Tissues of Experimentally Infected Mice. PLoS Neglected Tropical Diseases, 2013, 7, e2404.   | 3.0 | 49        |
| 2 | Insights from animal models on the immunogenetics of leprosy: a review. Memórias Do Instituto Oswaldo Cruz, 2012, 107, 197-208.  | 1.6 | 40        |
| 3 | Isolation of <i>Mycobacterium lepromatosis</i> and Development of Molecular Diagnostic Assays to Distinguish <i>Mycobacterium leprae</i> and <i>M. lepromatosis</i> . Clinical Infectious Diseases, 2020, 71, e262-e269. | 5.8 | 37        |
| 4 | Susceptibility and resistance in leprosy: Studies in the mouse model. Immunological Reviews, 2021, 301, 157-174.   | 6.0 | 16        |
| 5 | Differential growth of <i>Mycobacterium leprae</i> strains (SNP genotypes) in armadillos. Infection, Genetics and Evolution, 2018, 62, 20-26.  | 2.3 | 12        |
| 6 | IL-10 and NOS2 Modulate Antigen-Specific Reactivity and Nerve Infiltration by T Cells in Experimental Leprosy. PLoS Neglected Tropical Diseases, 2014, 8, e3149.   | 3.0 | 11        |
| 7 | Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy. PLoS Neglected Tropical Diseases, 2020, 14, e0008583.    | 3.0 | 7         |
| 8 | A Sensitive and Quantitative Assay to Enumerate and Measure <i>Mycobacterium leprae</i> Viability in Clinical and Experimental Specimens. Current Protocols, 2022, 2, e359.  | 2.9 | 4         |